INDEPENDENT AUDITOR’S REPORT
INDEPENDENT AUDITOR’S REPORT
–
–
–
–
– – –
–
–
–
–
–
–
–
PT KIMIA FARMA (PERSERO) Tbk. DAN ENTITAS ANAK LAPORAN ARUS KAS KONSOLIDASIAN UNTUK TAHUN YANG BERAKHIR PADA TANGGAL 31 DESEMBER 2015 (Disajikan dalam Rupiah, kecuali dinyatakan lain)
PT KIMIA FARMA (PERSERO) Tbk. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR YEARS ENDED DECEMBER 31, 2015 (Expressed in Rupiah, unless otherwise stated)
31 Des 2015 / Dec 31, 2015 ARUS KAS DARI AKTIVITAS OPERASI Penerimaan dari pelanggan Pembayaran kepada pemasok Pembayaran kepada karyawan Pembayaran beban usaha Pembayaran bunga Pembayaran pajak penghasilan Jaminan Bank Restitusi Pajak Penerimaan operasi lain-lain Arus kas neto dari aktivitas operasi
31 Des 2014 / Dec 31, 2014
5.160.269.176.733 (3.486.460.569.159) (838.721.290.772) (689.390.118.248) (36.142.085.429) (68.190.694.925) 222.397.958 102.013.237.293 32.366.808.898
4.858.544.021.925 (3.213.395.602.045) (768.088.674.290) (607.343.492.578) (21.869.685.415) (50.181.904.235) (865.969.111) 60.804.533.005 28.706.028.125
175.966.862.348
286.309.255.381
ARUS KAS DARI AKTIVITAS INVESTASI Penerimaan bunga Perolehan aset tetap : Aset tetap Beban tangguhan Hasil penjualan aset tetap Penambahan biaya tangguhan eksplorasi dan pengembangan Investasi pada entitas asosiasi Aset tidak berwujud Penerimaan Dividen Arus kas neto untuk aktivitas investasi
11.970.064.411
7.258.813.883
(146.204.582.173) (106.689.146.191) 1.120.745.180
(102.413.131.061) (85.889.115.753) 14.944.001.857
(426.621.047)
-
(3.179.575.954) 14.906.196.563
(165.324.992.700) (164.000.000) -
(228.502.919.211)
(331.588.423.774)
ARUS KAS DARI AKTIVITAS PENDANAAN
CASH FLOWS FROM OPERATING ACTIVITIES Receipt from customer Payment to suppliers Payment to employees Payment of operating expenses Payment of interest loan Payment of income taxes Bank warranty Tax restitution Other disbursement from operating Net cash provided from operating activities CASH FLOWS FROM INVESTING ACTIVITIES Interest receipt Acquisition offixedassets: Fixed assets Deferred expense Selling of fixed assets Addition of deferred exploration and development costs Investment in association Intangible asset
Net cash use for investing activities CASH FLOWS FROM FINANCING ACTIVITIES Addition medium term notes
Penambahan utang bank jangka menengah Penambahan (pembayaran) utang bank jangka pendek Pembayaran dividen Angsuran utang sewa pembiayaan Kepentingan non pengendali
(11.170.980.893)
200.000.000.000 84.139.567.948
(46.925.135.841) (1.734.020.601) -
(53.855.793.068) (1.468.516.370) (4.325.732.268)
Dividend payment Installment of finance leaseddebt Non controlling interest
Arus kas neto dari (untuk) aktivitas pendanaan
(59.830.137.335)
224.489.526.242
Net cash provided from (use for) financing activities
(112.366.194.197)
179.210.357.849
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
KAS DAN SETARA KAS AWAL TAHUN
573.360.267.681
394.149.909.832
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR
KAS DAN SETARA KAS AKHIR TAHUN
460.994.073.484
573.360.267.681
CASH AND CASH EQUIVALENTS AT ENDING OF THE YEAR
KENAIKAN (PENURUNAN) BERSIH KAS DAN SETARA KAS
Catatan atas laporan keuangan konsolidasian terlampir merupakan bagian yang tidak terpisahkan dari laporan keuangan konsolidasian secara keseluruhan.
Addition (payment) short term loan
The accompanying notes to consolidated financial statement are an integral part of these consolidated financial statements.
-5-
“” didirikan berdasarkan akta No. 18 tanggal
PT Kimia Farma (Persero) Tbk. the “”,was ’s Articles of Association has
’s head
’s
The Entity’s
’s
’s goals and objectives are to
both from the Entity’sown production and from
’s shares before
ekuitas pada bagian “tambahan modal disetor”.
control entities in equity as part of “paid in capital”.
numbers of Entity’s Subsdiaries employees are
KEUANGAN (“PSAK”) DAN INTERPRETASI STANDAR AKUNTANSI KEUANGAN (“ISAK”) BARU DAN REVISI
FINANCIAL ACCOUNTING STANDARDS (“PSAK”) AND STANDARDS (“ISAK”)
akuntansi keuangan (“SAK”) dan intrepretasi standar akuntansi keuangan (“ISAK”) baru dan revisi yang
1 (Revisi 2013), “Penyajian Laporan Keuangan”. “Laporan Laba Rugi Komprehensif” telah berubah menjadi “Laporan Laba Rugi dan Penghasilan Komprehensif Lain”. Perubahan tersebut mengharuskan
1 (Revised 2013), “Presentation of Financial Statements”. 1 for the “Statement of Comprehensive Income” has changed to “Statement of Profit or Loss and Other Comprehensive Income”.
KEUANGAN (“PSAK”) DAN INTERPRETASI STANDAR AKUNTANSI KEUANGAN (“ISAK”) BARU DAN REVISI
ACCOUNTING STANDARDS (“PSAK”) AND STANDARDS (“ISAK”)
4 (Revisi 2013), “Laporan Keuangan Tersendiri”. PSAK 4 revisi telah diubah namanya menjadi “Laporan Keuangan Tersendiri”; PSAK ini berlanjut menjadi standar
4 (Revised 2013), “Separate Financial Statements”. 4 (Revised 2009) has been renamed “Separate Financial Statements”; it continues to be a standard
15 (Revisi 2013), “Investasi pada Entitas Asosiasi dan Ventura Bersama”. PSAK ini menggantikan (Revisi 2009) “Investasi pada Entitas Asosiasi”. pada Entitas Asosiasi dan Ventura Bersama”. Entitas tidak
PSAK 15 (Revised 2013), “Investments in Joint Ventures”. Thi (Revised 2009) “Investment in Associates”. Joint “Investments in Associates and Joint Ventures”. Entities
24 (Revisi 2013), “Imbalan Kerja”. “jangka pendek” dan “jangka panjang lain”, perlakuan
between “short term” and “other longterm” benefits, treatment of
46 (Revisi 2014), “Pajak Penghasilan”. 2010). Revisi ini menekankan bahwa konsep “laba fiskal” Kontinjensi, dan Aset Kontinjensi” sebagai
concept of ‘taxable profit’ implies a net rather than gross 57 “Provisions, Contingent Liabilities, and Contingent Assets” instead and amendment to deferred
48 (Revisi 2013), “Penurunan Nilai Asset”. “Pengukuran Nilai Wajar”. Standar ini menegaskan “Segmen Operasi”) sebelum penggabungan.
68, ‘Fair value measurement’. The standard re 5 ‘Operating Segments’) before aggregation.
KEUANGAN (“PSAK”) DAN INTERPRETASI STANDAR AKUNTANSI KEUANGAN (“ISAK”) BARU DAN REVISI
FINANCIAL ACCOUNTING STANDARDS (“PSAK”) AND STANDARDS (“ISAK”)
50 (Revisi 2014), “Instrumen Keuangan: Penyajian”. 50 (Revisi 2010) “Instrumen Keuangan: Penyajian”, adalah untuk meningkatkan pengungkapan
55 (Revisi 2014), “Instrumen Keuangan: Pengakuan dan Pengukuran”.
55 (Revised 2014), “Financial Instruments: Recognition and Measurement”. 68 “Fair value measurement”’. Two other
014), “Instrumen Keuangan: Pengungkapan”.
60 (Revised 2014), “Financial Instruments: Disclosures”.
65, “Laporan Keuangan Konsolidasi”. 2009), “Konsolidasi dan Laporan Keuangan Tersendiri”, 7 (Revisi 2009), “Konsolidasi Bertujuan Khusus”.
4 (Revised 2009), “Consolidated and Separate Financial Statements”, and “Consolidation Special Purpose Entities”.
66, “Pengaturan Bersama”.
66, “Joint Arrangements”. “Interests in Joint Ventures” and “Jointly Controlled Entities: Non Contributions by Venturer” for the accounting of joint
PSAK 67, “Pengungkapan Kepen Lain”.
PSAK 67, “Disclosures of Interests in Other Entities”. “Consolidated Financial Statements”, and PSAK 66, “Joint Arrangements”. The disclosures are required in
KEUANGAN (“PSAK”) DAN INTERPRETASI STANDAR AKUNTANSI KEUANGAN (“ISAK”) BARU DAN REVISI
(“PSAK”) AND STANDARDS (“ISAK”)
68, “Pengukuran Nilai Wajar”. penawaran dan permintaan (“bid and ask”), premis
68, “Fair Value Measurements”.
’s operation have been adopted as disclosed in the “Summary of Significant Accounting Polices”.
’s
–
“Consolidated Financial Statements and Separate ial Statements” retrospectively
reclassifies the parent’s share of components
PSAK 55 (Revisi 2011), “Instrumen Keuangan: Pengakuan dan Pengukuran”.
PSAK 55 (Revisi 2011), “Instrumen Keuangan: Pengakuan dan Pengukuran”.
The Entity’s investments in its associates are accounted for acquisition) as adjusted for changes in the Company’s
Equity in Associates’ losses which exceeds the carrying
the Company’s share in the results of operations of the
pany’s share in
“Pengungkapan Pihakpihak Berelasi”.
7 (Revised 2010), “Related Party Disclosures”.
PSAK 50 (Revisi 2010) “Instrumen Keuangan: Penyajian”, PSAK 55 (Revisi 2011) “Instrumen Keuangan: Pengakuan dan Pengukuran”, dan PSAK 60 “Instrumen Keuangan: Pengungkapan”.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
“Pengukuran Nilai Wajar”
are willing to (arm’s length transactions), refer “Fair Value Measurement”
•
•
•
•
•
•
“pendapatan bunga” dalam laporan
“lain”.
“Aset Lainlain”.
“other assets”.
2011), “Sewa” yang efektif berlaku untuk periode pelaporan
rapkan PSAK 23 (Revisi 2010) “Pendapatan”. PSAK
23 (Revised 2010) “Revenue”.
Pajak Pertambahan Nilai (“PPN”).
”Uang Muka Pelanggan“.
“Advances from Customers”.
) “Imbalan Kerja” secara retrospektif dan merubah metode akuntansinya
) “Employee Benefits”,
“projected unit credit”.
Pemberitahuan (“SPT”) Tahunan sehubungan dengan situasi
(Revisi 2009), “Segmen Operasi”. PSAK ini mensyaratkan
(Revised 2009), “Operating Segment”. This
liabilities are recognized in accordance with the Group’s
the Group’s profit or loss. More de
provided based on the Group’s evaluation on industry
PSAK 57 (Revisi 2009), “Provisi, Liabilitas Kontijensi dan Aset Kontijensi”. Kelompok Usaha membuat analisis untuk semua
–
– –
– – –
Employee’s loan
450,000 shares change into 210,000 shares with the Entity’
while there is only pharmacy’s branch.
% of the Entity’s asset value. I
’s
–
–
–
–
– June 13, 2014 until June 13, 2015, the Entity’s loan as of
–
ies equal to entity’s tax return
–
Doctor’s medical service
Entity and its employees. Employees’ and the Entity’s
menggunakan metode “”.
Aktuaria, independent actuary, by using the “Projected Unit Credit” method.
amounts depend on the employee’s service period, based on
aktuaris independen dengan menggunakan metode “ ”
– , using the “Projected Unit Credit” method
karyawan berdasarkan PSAk 24 (revisi) 2013 “Imbalan Kerja”
- -
–
- -
–
–
–
–
–
–
Director and commissioner’s salary
–
–
Enterprise’ Owned Enterprise’
–
managing 80 % of the Entity’s factory production c
’s product
’s products in each areas of their
Farma’s product in
Entity’s main activities are distribution and marketing of
’s information segment is pr
–
’s
’
’
menetapkan kebijakan “ecatalog” yang dengan kebijakan
“”
– –
– –
–